Skip to content

Effect of Plasma Rich in Growth Factors on Semen Quality

Effect of Plasma Rich in Growth Factors (PRGF) on Semen Quality

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02708537
Enrollment
20
Registered
2016-03-15
Start date
2016-04-30
Completion date
2017-12-31
Last updated
2022-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Endothelial Growth Factor Overexpression

Brief summary

The hypothesis is growing semen samples with plasma rich in growth factors (PRGF), because it could improve sperm motility in patients subsidiary TRA, ultimately improving pregnancy rates.

Detailed description

Platelet growth factors are a group of proteins involved in cellular communication modifying biological responses. Obtaining plasma rich in growth factors is already widespread and simple protocol technique that is being used in various areas of medicine with superb results. Described many of the growth factors present in the PRGF are related to sperm parameters, especially motility The described effects have been studied in mammalian and each growth factor individually. PRGF contains a pool of growth factors and therefore be interesting to analyze their effect on various sperm parameters. One of those parameters is very important for fertilization sperm motility, since the lack of it will prevent displacement by the cervix to meet the egg in the fallopian tube.

Interventions

BIOLOGICALPRGF in candidates for sperm donors

PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.

Sponsors

bTI Vitoria
CollaboratorUNKNOWN
IVI Bilbao
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-35 years * more than 5 million sperm per milliliter

Exclusion criteria

* Not having genetic and infectious diseases * Do not suffer mental illness * Have a family study determined that there is no risk of hereditary diseases * There have fathered more than 6 children in the country

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the percentage of motile sperm adding PRGF versus those samples that growth factors were not added6 monthsWithin concerted donor visits in IVI Bilbao will be held: * Removing Blood 9 mL of blood to obtain plasma rich in factors growth * Seminogram to analyze all semen parameters according to the criteria of the WHO (2010), paying particular attention to sperm motility. * Sperm vitality will be analyzed before and after treatment with PRGF. PRGF application on the seminal aliquots will be conducted at different concentrations assessing sperm motility.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026